TY - JOUR
T1 - Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population
AU - Sigurdardottir, Gunnthorunn
AU - Alsterholm, Mikael
AU - Anderson, Chris D.
AU - Bradley, Maria
AU - Sandström Falk, Marihelen
AU - Johansson, Emma K.
AU - Lundqvist, Maria
AU - Sonesson, Andreas
AU - Svensson, Åke
AU - Theodosiou, Grigorios
AU - Vrang, Sophie
AU - Kobyletzki, Laura B.von
PY - 2024/6/19
Y1 - 2024/6/19
N2 - A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic der-matitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-AD™). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (inter-quartile range [IQR] 27–48). The participants consi-dered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-AD™ scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-AD™ was observed (p < 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluated by vIGA-AD™, affected RECAP scores significantly (p < 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows acceptable reliability.
AB - A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic der-matitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-AD™). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (inter-quartile range [IQR] 27–48). The participants consi-dered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-AD™ scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-AD™ was observed (p < 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluated by vIGA-AD™, affected RECAP scores significantly (p < 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows acceptable reliability.
KW - atopic dermatitis
KW - eczema
KW - patient-reported outcome measure
KW - validation study
U2 - 10.2340/actadv.v104.38889
DO - 10.2340/actadv.v104.38889
M3 - Article
C2 - 38898676
AN - SCOPUS:85196697694
SN - 0001-5555
VL - 104
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
M1 - adv38889
ER -